Organ Transplant-Focused TransMedics Clocks Q4 Profit On Increased Use Of Its Organ Care System, Analysts Optimistic About Integrated Aviation Business
Portfolio Pulse from Vandana Singh
TransMedics Group Inc (NASDAQ:TMDX) reported a Q4 profit with revenue of $81.2 million, up 159% Y/Y, surpassing the consensus of $68.51 million. The growth was attributed to increased use of its Organ Care System (OCS) and new logistics services. EPS was $0.12, beating the expected loss of $(0.03). The company expects FY 2024 revenues of $360-$370 million, above the consensus of $330.23 million. Oppenheimer raised TMDX's price target from $92 to $105 with an Outperform rating, and William Blair maintains an Outperform rating, highlighting the company's strong Q4 results and promising outlook.
February 27, 2024 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics reported a significant Q4 profit, with revenue growth of 159% Y/Y, and EPS of $0.12, surpassing expectations. The company forecasts FY 2024 revenues to exceed consensus, supported by increased OCS utilization and new logistics services. Analysts from Oppenheimer and William Blair are optimistic, with raised price targets and Outperform ratings.
The positive earnings report, exceeding revenue expectations, and optimistic future revenue guidance directly impact TMDX's stock value. Analyst upgrades and positive outlooks from reputable financial firms further bolster investor confidence, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100